Experimental drug for brittle bones tested in small trial
NCT ID NCT05231668
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a single dose of a drug called SAR439459 in 16 adults with osteogenesis imperfecta (brittle bone disease). The drug aims to block a protein that may weaken bones. The study focused on safety and how the drug moves through the body, but it was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR439459 (a monoclonal antibody that blocks TGFβ)
What this could lead to
If successful, this could point toward a new treatment to strengthen bones and reduce fractures in people with osteogenesis imperfecta.
What could go wrong
This was a very early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine - Site Number:8400003
Houston, Texas, 77030, United States
-
Bone Research and Education Centre_Site Number :1240003
Oakville, Ontario, L6M 1M1, Canada
-
Cincinnati Children's Hospital Medical Center Site Number : 8400010
Cincinnati, Ohio, 45229, United States
-
Department of Medicine/ School of Clinical Sciences at Monash Health Monash University_246 Clayton Road_Site Number :0360002
Clayton, Victoria, 3168, Australia
-
Hopital Edouard Herriot _Site Number :2500002
Lyon, 69003, France
-
Hopital Lariboisiere_Site Number :2500001
Paris, 75010, France
-
Indiana University School of Medicine_Site Number: 8400002
Indianapolis, Indiana, 46202, United States
-
Kennedy Krieger Institute_Site number 8400004
Baltimore, Maryland, 21205, United States
-
Toronto general Hospital_Site Number :1240002
Toronto, M5G 2C4, Canada
-
UCLA Health_Site Number: 8400006
Los Angeles, California, 90095, United States
-
Vanderbilt University Site Number : 8400011
Nashville, Tennessee, 37232, United States
-
Westmead Hospital_Site Number :0360003
Westmead, New South Wales, 2145, Australia
-
Yale University - Site Number:8400007
New Haven, Connecticut, 06510, United States